There is no website visitor data available for this stock.
---
QLGN FAQ
What was Qualigen Therapeutics Inc’s price range in the past 12 months?
Qualigen Therapeutics Inc lowest stock price was $0.28 and its highest was $1.26 in the past 12 months.
What is Qualigen Therapeutics Inc’s market cap?
Currently, no data Available
When is Qualigen Therapeutics Inc’s upcoming earnings report date?
Qualigen Therapeutics Inc’s upcoming earnings report date is May 10, 2024 which is in 20 days.
How were Qualigen Therapeutics Inc’s earnings last quarter?
Qualigen Therapeutics Inc released its earnings results on Mar 29, 2024. The company reported -$0.466 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.054.
Qualigen Therapeutics Inc does not currently pay dividends.
What is Qualigen Therapeutics Inc’s EPS estimate?
Qualigen Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qualigen Therapeutics Inc have?
Qualigen Therapeutics Inc has 6,307,371 shares outstanding.
What happened to Qualigen Therapeutics Inc’s price movement after its last earnings report?
Qualigen Therapeutics Inc reported an EPS of -$0.466 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 5.714%.
Which hedge fund is a major shareholder of Qualigen Therapeutics Inc?
Currently, no hedge funds are holding shares in QLGN
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.